5mg vial of semaglutide - 5 MG Semaglutide/B12 Injectable (2mL vial) |

The FDA didnt approve daily use of GLP-1 receptor agonist for good reasons

Safety Profile Comparison All three compounds share a similar gastrointestinal side effect profile nausea, diarrhea, vomiting, and constipation are the most commonly reported adverse events, occurring more frequently at higher doses

Although costs of some have gone down recently, branded GLP-1s are typically $499/month and up, if you are paying out of pocket

Petropoulos, I

Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease

Result After using the Medicube PDRN Pink Glutathione Serum Mist 100ml, your skin immediately feels fresh, hydrated and comfortable